Beacon secures $170m to advance ophthalmic gene therapies

Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).

Jul 4, 2024 - 04:00

Beacon secures $170m to advance ophthalmic gene therapies

Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).

Read the original article

Tags:

Previous Article

Mapping the surfaces of MXenes, atom by atom, reveals new potential for the 2D m...

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans

STAT+: Karuna’s treatment for schizophrenia achieves st...

Mar 20, 2023

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

Sandoz concludes acquisition of Mycamine antifungal agent from Astellas

Sandoz concludes acquisition of Mycamine antifungal age...

Aug 28, 2023